Nevertheless, these studies suggest that the genetic or epigenetic downregulation of B-Myb in the absence of functional pVHL facilitates tumor initiation and growth, and that a drug that stabilizes B-Myb may be used to potentially treat renal cell carcinomas. This evidence concerns the gene VHL and hereditary clear cell renal cell carcinoma.